HospiceChoice Rx Welcomes Shelly Mikuls as New Director

HospiceChoice Rx Welcomes New Leadership

HospiceChoice Rx is delighted to announce the addition of Shelly Mikuls to its team as the new Director of Business Development. Starting in January, she will use her vast experience to enhance the company’s operational strategies. With over 17 years working in the hospice sector, including a significant role at a Hospice Pharmacy Benefits Manager (PBM), her knowledge will be crucial in fostering essential relationships with Electronic Medical Record (EMR) partners.

Expertise in Hospice Management

Shelly's extensive background began with a master's degree in social work from Washington University's George Warren Brown School of Social Work. She initiated her career in the area of long-term care and flourished into leadership positions, making her adept at addressing both clinical and operational challenges faced by Hospice organizations. Her experience includes serving as an Executive Director for a startup Hospice and managing support services at a Hospice PBM, equipping her with a comprehensive understanding that will benefit Hospice clients.

Enhancing Training and Education Initiatives

Excitement fills the air about Shelly's new role at the company. Nick Opalich, CEO of HospiceChoice Rx, emphasized, "We prioritize educational programs for Hospice providers. Shelly’s experience will enrich our training initiatives for care teams and guide our regional sales directors. This welcomes new opportunities for our company as we move into 2025." Education remains a cornerstone of the company's strategy, combining operational insights with improved training for Hospice providers.

Innovative Technology in Hospice Care

HospiceChoice Rx is on a mission to transform how Hospice organizations manage their pharmacy benefits. The company’s innovative NaviScript technology serves as a channel to streamline medication ordering processes, assist with pharmacy claims efficiently, and, most importantly, give providers more time to focus on patient care. Shelly Mikuls reflects this ethos, stating, "My knowledge aligns with HospiceChoice Rx's commitment to delivering innovative PBM services that enhance clinical outcomes and operational efficiencies. I am eager to contribute to a company devoted to advancing Hospice care through technology."

Commitment to Cost Efficiency

Using this modern approach, HospiceChoice Rx positions itself as an important ally for Hospice and Palliative Care organizations aiming to improve prescribing workflows and potentially find opportunities for cost savings. The integration of such technologies not only streamlines processes but also helps in ensuring that patients receive timely and appropriate care.

About HospiceChoice Rx

HospiceChoice Rx specializes in providing state-of-the-art pharmacy benefits tailored exclusively for Hospice and Palliative Care organizations. Addressing the increasing pressure on hospices to reduce costs while optimally managing clinicians' time, the company developed the NaviScript platform specifically designed for these needs. The platform simplifies ePrescribing, reduces administrative workloads, and enhances patient care efficiencies by integrating seamlessly with existing EMR systems.

With a network exceeding 75,000 pharmacies nationwide, HospiceChoice Rx guarantees that patient medications are accessible right where they live. The company also fosters collaborations with preferred pharmacies to maintain essential regional relationships, ensuring quality in care delivery.

To further support hospice providers, the company offers PharmD clinical consultations, providing guidance on therapeutics and deprescribing alternatives, thus upholding high standards in patient welfare. For more information on how HospiceChoice Rx is transforming Hospice care, visit their website.

Frequently Asked Questions

What is the role of Shelly Mikuls at HospiceChoice Rx?

Shelly Mikuls serves as the Director of Business Development, utilizing her extensive experience in hospice management to enhance relationships with partners.

How does NaviScript benefit hospice organizations?

The NaviScript platform streamlines medication ordering processes, reduces administrative burdens, and prioritizes patient care through efficient pharmacy claims management.

What educational initiatives are being emphasized by HospiceChoice Rx?

The company focuses on training programs for hospice providers, ensuring staff are well-versed in effective practices and procedures within hospice care.

How does HospiceChoice Rx support medication access?

With a network of over 75,000 pharmacies, HospiceChoice Rx partners with preferred pharmacies to ensure patients can access their medications where they reside.

What are PharmD clinical consultations?

These are specialized consultations provided to hospice providers, aiming to offer guidance on therapeutic alternatives and deprescribing strategies to maintain quality patient care.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.